Retrospective comparison of individual risk factors hemithyroidectomy and thyroidectomy in patients with papillary carcinoma of the thyroid gland in combination with autoimmune thyroiditis

Introduction. Papillary thyroid carcinoma is the most common subtype of thyroid cancer as it comprises 95 % of cases. Frequently, this pathology develops in the presence of autoimmune thyroiditis (Hashimoto’s thyroiditis) which is the main cause of hypothyroidism in various rich in iodine regions. Papillary thyroid carcinoma is characterized by good prognosis, however some patients experience recurrence which depends on the volume of surgical intervention.

Aim. To compare clinical outcomes and complications after hemithyroidectomy (HE) and thyroidectomy (TE) in patients with papillary thyroid carcinoma secondary to autoimmune thyroiditis.

Materials and methods. The retrospective study included 2031 patients with papillary thyroid carcinoma. Considering individual risk factors, 67 patients were excluded from the HE group, and 588 patients were excluded from the TE group. Each group included 688 patients for whom data were matched. Such individual factors as age, sex, primary tumor size, extrathyroidal invasion, multifocal tumor and cervical lymph node metastasis were taken into account.

Results. During 10‑year follow-up, recurrence was diagnosed in 26 (3.8 %) patients of the HE group and 11 (1.6 %) patients of the TE group. Relative risk of recurrence was significantly lower after TE than after HE (risk ratio (RR) 0.41; 95 % confidence interval (CI) 0.21–0.81; р = 0.01). In the HE group, for the majority of patients recurrence was observed in the contralateral lobe of the thyroid (84.6 %). In the TE group, there were no recurrences in all patients. There were no significant differences between the groups after exclusion of recurrence in the contralateral thyroid lobe (RR 2.75; 95 % CI 0.08–8.79; р = 0.08). In the TE group, the number of patients with transient and permanent hypothyroidism in the TE group was significantly higher than in the HE group (р <0.001).

Conclusion. Hemithyroidectomy is appropriate for the majority of patients with papillary thyroid carcinoma in the absence of extrathyroidal invasion in the neighboring tissues per preoperative examination. For patients after HE, preoperative and postoperative diagnostic examinations are important as most recurrences develop in the contralateral thyroid lobe.

1. Cho B.Y., Choi H.S., Park Y.J. et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23(7):797–804. DOI: 10.1089/thy.2012.0329

2. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164

3. Elisei R., Molinaro E., Agate L. et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95(4):1516–27. DOI: 10.1210/jc.2009-1536

4. McNally R.J., Blakey K., James P.W. et al. Increasing incidence of thyroid cancer in great Britain, 1976–2005: age-period-cohort analysis. Eur J Epidemiol 2012;27(8):615–22. DOI: 10.1007/s10654-012-9710-x

5. Jeon M.J., Kim W.G., Choi Y.M. et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 2016;26(1):161–8. DOI: 10.1089/thy.2015.0375

6. Kim S.K., Park I., Woo J.W. et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8676 patients at a single institution. Surgery 2017;161(2):485–92. DOI: 10.1016/j.surg.2016.07.037

7. Siddiqui S., White M.G., Antic T. et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 2016;26(6):807–15. DOI: 10.1089/thy.2015.0429

8. Yu X.M., Wan Y., Sippel R.S., Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18 445 cases. Ann Surg 2011;254(4):653–60. DOI: 10.1097/SLA.0b013e318230036d

9. Mercante G., Frasoldati A., Pedroni C. et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009;19(7):707–16. DOI: 10.1089/thy.2008.0270

10. Pazaitou-Panayiotou K., Capezzone M., Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17(11):1085–92. DOI: 10.1089/thy.2007.0005

11. Pisanu A., Saba A., Podda M. et al. Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine 2015;48(2):575– 81. DOI: 10.1007/s12020-014-0350-7

12. Pyo J.S., Sohn J.H., Kang G. Detection of tumor multifocality is important for prediction of tumor recurrence in papillary thyroid microcarcinoma: a retrospective study and meta-analysis. J Pathol Transl Med 2016;50(4):278–86. DOI: 10.4132/jptm.2016.03.29

13. Ross D.S., Litofsky D., Ain K.B. et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009;19(10):1043–8. DOI: 10.1089/thy.2008.0407

14. Chow S.M., Law S.C., Chan J.K. et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40. DOI: 10.1002/cncr.11442

15. Ahn H.S., Kim H.J., Welch H.G. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. New Engl J Med 2014;371(19):1765–7. DOI: 10.1056/NEJMp1409841

16. Ahn H.S., Welch H.G. South Korea’s thyroid-cancer “epidemic”: turning the tide. New Engl J Med 2015;373(24):2389–90. DOI: 10.1056/NEJMc1507622

17. Ito Y., Miyauchi A., Kihara M. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24(1):27–34. DOI: 10.1089/thy.2013.0367

18. Lang B.H., Wong C.K. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol 2015;173(3):367–75. DOI: 10.1530/EJE-15-0454

19. Kwak J.Y. Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab 2013;28(2):81–5. DOI: 10.3803/EnM.2013.28.2.81

20. Haugen B.R., Alexander E.K., Bible K.C. et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1– 133. DOI: 10.1089/thy.2015.0020

21. Lang B.H., Chan D.T., Chow F.C. et al. The association of discolored parathyroid glands and hypoparathyroidism following total thyroidectomy. World J Surg 2016;40(7):1611–7. DOI: 10.1007/s00268-016-3462-9

22. Bollerslev J., Rejnmark L., Marcocci C. et al. European Society of Endocrinology. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 2015;173(2):G1–20. DOI: 10.1530/EJE-15-0628

23. Bilimoria K.Y., Bentrem D.J., Ko C.Y. et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246(3):375–81, discussion 381–474. DOI: 10.1097/SLA.0b013e31814697d9

24. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63. DOI: 10.1210/jcem.86.4.7407

25. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110

26. Nixon I.J., Ganly I., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9. DOI: 10.1016/j.surg.2011.08.016

27. Barney B.M., Hitchcock Y.J., Sharma P. et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011;33(5):645–9. DOI: 10.1002/hed.21504

28. Haigh P.I., Urbach D.R., Rotstein L.E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12(1):81–9. DOI: 10.1007/s10434-004-1165-1

29. Kandil E., Krishnan B., Noureldine S.I. et al. Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications. ORL J Otorhinolaryngol Its Relat Spec 2013;75(1):6–17. DOI: 10.1159/000345498

30. Hauch A., Al-Qurayshi Z., Randolph G., Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014;21(12):3844–52. DOI: 10.1245/s10434-014-3846-8

31. Han J.M., Kim W.G., Kim T.Y. et al. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid 2014;24(5):820–5. DOI: 10.1089/thy.2013.0362

32. Jeon M.J., Kim W.G., Choi Y.M. et al. Recent changes in the clinical outcome of papillary thyroid carcinoma with cervical lymph node metastasis. J Clin Endocrinol Metab 2015;100(9):3470–7. DOI: 10.1210/JC.2015-2084